» Articles » PMID: 15292258

Heparan Sulfate/heparin Oligosaccharides Protect Stromal Cell-derived Factor-1 (SDF-1)/CXCL12 Against Proteolysis Induced by CD26/dipeptidyl Peptidase IV

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Aug 5
PMID 15292258
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Stromal cell-derived factor-1 (SDF-1) is a CXC chemokine that is constitutively expressed in most tissues and displayed on the cell surface in association with heparan sulfate (HS). Its numerous biological effects are mediated by a specific G protein-coupled receptor, CXCR4. A number of cells inactivate SDF-1 by specific processing of the N-terminal domain of the chemokine. In particular, CD26/dipeptidyl peptidase IV (DPP IV), a serine protease that co-distributes with CXCR4 at the cell surface, mediates the selective removal of the N-terminal dipeptide of SDF-1. We report here that heparin and HS specifically prevent the processing of SDF-1 by DPP IV expressed by Caco-2 cells. The level of processing increases with the level of differentiation of these cells, which correlates with an increase of DPP IV activity. A mutant SDF-1 that does not interact with HS is readily cleaved by DPP IV, a process that is not inhibited by HS, demonstrating that a productive interaction between HS and SDF-1 is required for the protection to take place. Moreover, we found that protection depends on the degree of polymerization of the HS sulfated S-domains. Finally a structural model of SDF-1, in complex with HS oligosaccharides of defined length, rationalizes the experimental data. The mechanisms by which HS regulates SDF-1 may thus include, in addition to its ability to locally concentrate the chemokine at the cell surface, a control of selective protease cleavage events that directly affect the chemokine activity.

Citing Articles

Protection of stromal cell-derived factor-1 SDF-1/CXCL12 against proteases yields improved skin wound healing.

Pereira R, EzEldeen M, Ugarte-Berzal E, Vandooren J, Martens E, Gouwy M Front Immunol. 2024; 15:1359497.

PMID: 39156898 PMC: 11327020. DOI: 10.3389/fimmu.2024.1359497.


Development and Characterization of Heparin-Containing Hydrogel/3D-Printed Scaffold Composites for Craniofacial Reconstruction.

Brown N, Ellerbe L, Hollister S, Temenoff J Ann Biomed Eng. 2024; 52(8):2287-2307.

PMID: 38734845 DOI: 10.1007/s10439-024-03530-z.


Scarring Skin: Mechanisms and Therapies.

Lin X, Lai Y Int J Mol Sci. 2024; 25(3).

PMID: 38338767 PMC: 10855152. DOI: 10.3390/ijms25031458.


Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients.

Cambier S, Beretta F, Portner N, Metzemaekers M, de Carvalho A, Martens E Cell Mol Life Sci. 2023; 80(8):234.

PMID: 37505242 PMC: 11073220. DOI: 10.1007/s00018-023-04870-0.


Validation of Recombinant Heparan Sulphate Reagents for CNS Repair.

Lindsay S, Smith R, Yates E, Cartwright C, Thacker B, Turnbull J Biology (Basel). 2023; 12(3).

PMID: 36979099 PMC: 10044841. DOI: 10.3390/biology12030407.